|
Market Closed -
Nasdaq
06:00:00 22/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 834.04 USD | +0.90% |
|
+3.80% | +8.05% |
| 20/08 | Regeneron Pharmaceuticals Wins US FDA Approval For Pasatru In Ultra-Rare Musculoskeletal Condition | MT |
| 20/08 | US FDA approves Regeneron's rare bone disorder drug | RE |
| Market Cap | 83.28B 71.34B 66.75B 61.1B 115B 7,968B 116B 789B 308B 4,003B 313B 306B 13,240B | P/E 2026 * |
19.3x | P/E 2027 * | 16.6x |
|---|---|---|---|---|---|
| Enterprise Value | 76.41B 65.46B 61.25B 56.06B 105B 7,311B 107B 724B 282B 3,673B 287B 281B 12,148B | EV / Sales 2026 * |
4.52x | EV / Sales 2027 * | 3.95x |
| Free-Float |
71.07% | Yield 2026 * |
0.47% | Yield 2027 * | 0.53% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +0.90% | ||
| 1 week | +3.80% | ||
| Current month | +9.36% | ||
| 1 month | +28.08% | ||
| 3 months | +30.55% | ||
| 6 months | +6.97% | ||
| Current year | +8.05% |
| 1 week | 795.73 |  | 847 |
| 1 month | 654.05 | | 847 |
| Current year | 591.52 | | 847 |
| 1 year | 541 | | 847 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 19/8/26 | Fiscal year | General Counsel | 33,583 | 0.0326% | ||
| 18/8/26 | Fiscal year | Chief Financial Officer | 17,165 | 0.0167% | ||
| 10/8/26 | Fiscal year | Director | 1,200 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.90% | +3.80% | +41.49% | -0.78% | 83.28B | |
| +8.86% | +129.20% | +435.14% | +24.85% | 57.94B | |
| -1.69% | +23.30% | -22.30% | -36.29% | 57.77B | |
| -1.46% | +0.19% | -2.06% | +30.50% | 51.75B | |
| +1.74% | +4.43% | +12.37% | +169.64% | 49.35B | |
| +1.13% | +3.31% | +55.61% | -17.57% | 32.03B | |
| +0.46% | +6.37% | +50.29% | +97.27% | 25.91B | |
| +1.19% | +9.17% | +2.97% | +230.86% | 22.74B | |
| -0.30% | +4.45% | +58.29% | +118.84% | 16.87B | |
| -5.74% | +1.91% | -1.42% | +795.59% | 16.08B | |
| Average | +0.51% | +18.61% | +63.04% | +141.29% | 41.37B | |
| Weighted average by Cap. | +1.16% | +24.08% | +77.34% | +75.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.92B 14.49B 13.56B 12.41B 23.3B 1,619B 23.61B 160B 62.49B 813B 63.54B 62.16B 2,690B | 18.42B 15.78B 14.76B 13.51B 25.36B 1,762B 25.69B 174B 68.01B 885B 69.16B 67.65B 2,928B |
| Net income | 4.77B 4.09B 3.83B 3.5B 6.57B 457B 6.66B 45.2B 17.63B 229B 17.92B 17.53B 759B | 5.45B 4.66B 4.36B 4B 7.5B 521B 7.6B 51.56B 20.11B 262B 20.45B 20B 866B |
| Net Debt | -6.87B -5.88B -5.5B -5.04B -9.46B -657B -9.58B -65.04B -25.36B -330B -25.79B -25.23B -1,092B | -10.55B -9.04B -8.46B -7.74B -14.53B -1,010B -14.72B -99.94B -38.97B -507B -39.63B -38.77B -1,678B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/08/26 | USD 834.04 | +0.90% | 786,921 |
| 20/08/26 | USD 826.64 | -1.69% | 596,474 |
| 19/08/26 | USD 840.84 | +3.78% | 750,445 |
| 18/08/26 | USD 810.24 | +0.53% | 779,072 |
| 17/08/26 | USD 805.93 | +0.30% | 541,306 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
